September 11, 2017
Sanofi, Regeneron’s asthma study meets two primary endpoints
The pivotal Phase 3 Libery ASthma Quest study of dupilumab in a broad population of patients with uncontrolled, persistent asthma…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sanofi
September 8, 2017
Cemiplimab gets FDA breakthrough therapy designation for certain cell carcinoma
Sanofi and Regeneron Pharmaceuticals, said on Friday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to…
August 28, 2017
Sanofi buys US-based Protein Sciences
Sanofi has acquired USA based Protein Sciences, a vaccines biotechnology company located in Meriden, Connecticut. The Federal Trade Commission’s approval…
July 24, 2017
Sanofi, Regeneron seek European approval for approval in Europe for Dupinext to treat adults with atopic dermatitis
Sanofi and Regeneron Pharmaceuticals, on Friday announced that the European Medicine Agency`s Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Dupixent.
July 20, 2017
Ablynx, Sanofi in multimillion euros deal for treating inflammatory disease
Ablynx and Sanofi have made a deal for research collaboration and global exclusive licensing agreement related to Nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases.
July 11, 2017
Sanofi to acquire U.S. based vaccines biotechnology company
Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States.
June 15, 2017
Sanofi launchase employee stock purchase plan
Sanofi has launched a stock purchase plan for its employees to connect them with its future development of the company.
June 12, 2017
Sanofi’s and Regeneron’s diabetes drug testing shows positive results
Sanofi and Regeneron Pharmaceuticals have reported positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes.
May 25, 2017
Diplomat to sell Sanofi’s and Regeneron’s rheumatoid arthritis drug in U.S.
Diplomat Pharmacy will sell Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab), recently approved by the FDA to treat adults with moderately to severely active rheumatoid arthritis (RA) who have an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs).
May 23, 2017
Sanofi and Regeneron win FDA approval for its rheumatoid arthritis drug
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).